Hawaii 2025 Regular Session

Hawaii Senate Bill SCR29 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	THE SENATE S.C.R. NO. 29 THIRTY-THIRD LEGISLATURE, 2025 STATE OF HAWAII SENATE CONCURRENT RESOLUTION requesting the auditor to assess the social and financial effects of mandatory health insurance coverage for biomarker testing.
2	2
3	3	THE SENATE S.C.R. NO. 29
4	4	THIRTY-THIRD LEGISLATURE, 2025
5	5	STATE OF HAWAII
6	6
7	7	THE SENATE
8	8
9	9	S.C.R. NO.
10	10
11	11	29
12	12
13	13	THIRTY-THIRD LEGISLATURE, 2025
14	14
15	15
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29	SENATE CONCURRENT
30	30
31	31	RESOLUTION
32	32
33	33
34	34
35	35
36	36
37	37	requesting the auditor to assess the social and financial effects of mandatory health insurance coverage for biomarker testing.
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45	WHEREAS, biomarker testing is an invaluable tool in the diagnosis, treatment, appropriate management, and ongoing monitoring of diseases or conditions; and WHEREAS, biomarker testing is the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker; and WHEREAS, biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to specific therapeutic interventions, including known gene-drug interactions for medications being considered for use or already being administered, and includes gene mutations, gene characteristics, and protein expression; and WHEREAS, biomarker tests have many different uses in clinical practice, including: (1) Disease screening tests, such as prostate-specific antigen; (2) Diagnostic tests, such as pathologic or histologic assessment of a tissue biopsy; (3) Predictive tests, which are used to predict patient response to specific treatments; (4) Treatment and posttreatment monitoring tests, which detect treatment complications or subsequent disease advancement; and (5) Prognostic tests for estimating risk or time to clinical outcomes: for example, aggressive cancers have a poorer prognosis than more indolent cancers; and WHEREAS, the predictive biomarker tests are used by health care providers to tailor treatment to a patient's clinical condition and treatment goals, leading to more effective and targeted interventions; and WHEREAS, biomarker tests are used to diagnose and tailor treatments for a number of diseases and conditions, including Alzheimer's disease, amyotrophic lateral sclerosis (also known as Lou Gehrig's disease), cancers (specifically, breast cancer, melanoma, ovarian cancer, pancreatic cancer, and prostate cancer), hyperlipidemia, hypertension, lupus, Parkinson's disease, preeclampsia, rheumatoid arthritis, and sickle cell disease; and WHEREAS, despite the fact that biomarker testing is essential to high-quality, personalized care to treat serious illness and enhance patients' quality of life, patients cannot easily access it; and WHEREAS, to address this restrictive access, House Bill No. 2223, H.D. 1, Regular Session of 2024 (HB2223 H.D. 1), required insurers, mutual benefit societies, and health maintenance organizations to provide coverage for medically necessary biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a person's disease or condition to guide treatment decisions when supported by medical and scientific evidence; and WHEREAS, the Legislature adopted House Concurrent Resolution No. 53, Regular Session of 2024 (HCR53), to fulfill the requirements of sections 23-51 and 23-52, Hawaii Revised Statutes, that require a concurrent resolution be passed for the Auditor to review and prepare a report assessing the social and financial effects of a proposed mandated health insurance coverage as proposed in HB2223 H.D. 1; and WHEREAS, in accordance with HCR53, the Auditor issued Report No. 25-01, "Assessment of Proposed Mandatory Health Insurance Coverage for Medically Necessary Biomarker Testing," in which the Auditor determined that there would be "no social or financial impacts caused by the mandate requiring that health insurance policies provide coverage for medically necessary biomarker testing" as proposed in HB2223 H.D. 1; and WHEREAS, the Auditor's determination was based on the responses by insurers stating that "their policies are already required to include coverage for medically necessary biomarker testing"; and WHEREAS, barriers to access still persist as insurers may delay determinations of a biomarker test's medical necessity or deny coverage of the test, further requiring the patient to either pay for the costs out-of-pocket or appeal the denial; and WHEREAS, accordingly, the coverage for biomarker tests should not be limited to when such tests are deemed to be medically necessary by the insurer's medical director, when the patient's health care provider, after assessing the patient and reviewing medical and scientific evidence, has already concluded that a test would be appropriate in the patient's circumstances; and WHEREAS, section 23-51, Hawaii Revised Statutes, requires that "[b]efore any legislative measure that mandates health insurance coverage for specific health services, specific diseases, or certain providers of health care services as part of individual or group health insurance policies, can be considered, there shall be concurrent resolutions passed requesting the auditor to prepare and submit to the legislature a report that assesses both the social and financial effects of the proposed mandated coverage"; and WHEREAS, section 23-51, Hawaii Revised Statutes, further provides that "[t]he concurrent resolutions shall designate a specific legislative bill that: (1) Has been introduced in the legislature; and (2) Includes, at a minimum, information identifying the: (A) Specific health service, disease, or provider that would be covered; (B) Extent of the coverage; (C) Target groups that would be covered; (D) Limitations on utilization, if any; and (E) Standards of care. For purposes of this part, mandated health insurance coverage shall not include mandated optionals."; and WHEREAS, section 23-52, Hawaii Revised Statutes, further specifies the minimum information required for assessing the social and financial impact of the proposed health coverage mandate in the Auditor's report; and WHEREAS, House Bill No. 553, H.D. 1, Regular Session of 2025, requires insurers, mutual benefit societies, and health maintenance organizations to provide coverage, beginning January 1, 2026, for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a person's disease or condition to guide treatment decisions when supported by medical and scientific evidence; now, therefore, BE IT RESOLVED by the Senate of the Thirty-third Legislature of the State of Hawaii, Regular Session of 2025, the House of Representatives concurring, that the Auditor is requested to assess the social and financial effects of mandating health insurance coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a person's disease or condition to guide treatment decisions when supported by medical and scientific evidence, as provided in House Bill No. 553, H.D. 1, Regular Session of 2025; and BE IT FURTHER RESOLVED that the Auditor is requested to submit a report of its findings and recommendations, including any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2026; and BE IT FURTHER RESOLVED that certified copies of this Concurrent Resolution be transmitted to the Auditor, Director of Commerce and Consumer Affairs, and Insurance Commissioner. OFFERED BY: _____________________________
46	46
47	47	WHEREAS, biomarker testing is an invaluable tool in the diagnosis, treatment, appropriate management, and ongoing monitoring of diseases or conditions; and
48	48
49	49
50	50
51	51	WHEREAS, biomarker testing is the analysis of a patient's tissue, blood, or other biospecimen for the presence of a biomarker; and
52	52
53	53
54	54
55	55	WHEREAS, biomarkers are characteristics that are objectively measured and evaluated as indicators of normal biological processes, pathogenic processes, or pharmacologic responses to specific therapeutic interventions, including known gene-drug interactions for medications being considered for use or already being administered, and includes gene mutations, gene characteristics, and protein expression; and
56	56
57	57
58	58
59	59	WHEREAS, biomarker tests have many different uses in clinical practice, including:
60	60
61	61
62	62
63	63	(1) Disease screening tests, such as prostate-specific antigen;
64	64
65	65
66	66
67	67	(2) Diagnostic tests, such as pathologic or histologic assessment of a tissue biopsy;
68	68
69	69
70	70
71	71	(3) Predictive tests, which are used to predict patient response to specific treatments;
72	72
73	73
74	74
75	75	(4) Treatment and posttreatment monitoring tests, which detect treatment complications or subsequent disease advancement; and
76	76
77	77
78	78
79	79	(5) Prognostic tests for estimating risk or time to clinical outcomes: for example, aggressive cancers have a poorer prognosis than more indolent cancers; and
80	80
81	81
82	82
83	83	WHEREAS, the predictive biomarker tests are used by health care providers to tailor treatment to a patient's clinical condition and treatment goals, leading to more effective and targeted interventions; and
84	84
85	85
86	86
87	87	WHEREAS, biomarker tests are used to diagnose and tailor treatments for a number of diseases and conditions, including Alzheimer's disease, amyotrophic lateral sclerosis (also known as Lou Gehrig's disease), cancers (specifically, breast cancer, melanoma, ovarian cancer, pancreatic cancer, and prostate cancer), hyperlipidemia, hypertension, lupus, Parkinson's disease, preeclampsia, rheumatoid arthritis, and sickle cell disease; and
88	88
89	89
90	90
91	91	WHEREAS, despite the fact that biomarker testing is essential to high-quality, personalized care to treat serious illness and enhance patients' quality of life, patients cannot easily access it; and
92	92
93	93
94	94
95	95	WHEREAS, to address this restrictive access, House Bill No. 2223, H.D. 1, Regular Session of 2024 (HB2223 H.D. 1), required insurers, mutual benefit societies, and health maintenance organizations to provide coverage for medically necessary biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a person's disease or condition to guide treatment decisions when supported by medical and scientific evidence; and
96	96
97	97
98	98
99	99	WHEREAS, the Legislature adopted House Concurrent Resolution No. 53, Regular Session of 2024 (HCR53), to fulfill the requirements of sections 23-51 and 23-52, Hawaii Revised Statutes, that require a concurrent resolution be passed for the Auditor to review and prepare a report assessing the social and financial effects of a proposed mandated health insurance coverage as proposed in HB2223 H.D. 1; and
100	100
101	101
102	102
103	103	WHEREAS, in accordance with HCR53, the Auditor issued Report No. 25-01, "Assessment of Proposed Mandatory Health Insurance Coverage for Medically Necessary Biomarker Testing," in which the Auditor determined that there would be "no social or financial impacts caused by the mandate requiring that health insurance policies provide coverage for medically necessary biomarker testing" as proposed in HB2223 H.D. 1; and
104	104
105	105
106	106
107	107	WHEREAS, the Auditor's determination was based on the responses by insurers stating that "their policies are already required to include coverage for medically necessary biomarker testing"; and
108	108
109	109
110	110
111	111	WHEREAS, barriers to access still persist as insurers may delay determinations of a biomarker test's medical necessity or deny coverage of the test, further requiring the patient to either pay for the costs out-of-pocket or appeal the denial; and
112	112
113	113
114	114
115	115	WHEREAS, accordingly, the coverage for biomarker tests should not be limited to when such tests are deemed to be medically necessary by the insurer's medical director, when the patient's health care provider, after assessing the patient and reviewing medical and scientific evidence, has already concluded that a test would be appropriate in the patient's circumstances; and
116	116
117	117
118	118
119	119	WHEREAS, section 23-51, Hawaii Revised Statutes, requires that "[b]efore any legislative measure that mandates health insurance coverage for specific health services, specific diseases, or certain providers of health care services as part of individual or group health insurance policies, can be considered, there shall be concurrent resolutions passed requesting the auditor to prepare and submit to the legislature a report that assesses both the social and financial effects of the proposed mandated coverage"; and
120	120
121	121
122	122
123	123	WHEREAS, section 23-51, Hawaii Revised Statutes, further provides that "[t]he concurrent resolutions shall designate a specific legislative bill that:
124	124
125	125
126	126
127	127	(1) Has been introduced in the legislature; and
128	128
129	129
130	130
131	131	(2) Includes, at a minimum, information identifying the:
132	132
133	133
134	134
135	135	(A) Specific health service, disease, or provider that would be covered;
136	136
137	137
138	138
139	139	(B) Extent of the coverage;
140	140
141	141
142	142
143	143	(C) Target groups that would be covered;
144	144
145	145
146	146
147	147	(D) Limitations on utilization, if any; and
148	148
149	149
150	150
151	151	(E) Standards of care.
152	152
153	153
154	154
155	155	For purposes of this part, mandated health insurance coverage shall not include mandated optionals."; and
156	156
157	157
158	158
159	159	WHEREAS, section 23-52, Hawaii Revised Statutes, further specifies the minimum information required for assessing the social and financial impact of the proposed health coverage mandate in the Auditor's report; and
160	160
161	161
162	162
163	163	WHEREAS, House Bill No. 553, H.D. 1, Regular Session of 2025, requires insurers, mutual benefit societies, and health maintenance organizations to provide coverage, beginning January 1, 2026, for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a person's disease or condition to guide treatment decisions when supported by medical and scientific evidence; now, therefore,
164	164
165	165
166	166
167	167	BE IT RESOLVED by the Senate of the Thirty-third Legislature of the State of Hawaii, Regular Session of 2025, the House of Representatives concurring, that the Auditor is requested to assess the social and financial effects of mandating health insurance coverage for biomarker testing for the purposes of diagnosis, treatment, appropriate management, or ongoing monitoring of a person's disease or condition to guide treatment decisions when supported by medical and scientific evidence, as provided in House Bill No. 553, H.D. 1, Regular Session of 2025; and
168	168
169	169
170	170
171	171	BE IT FURTHER RESOLVED that the Auditor is requested to submit a report of its findings and recommendations, including any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2026; and
172	172
173	173
174	174
175	175	BE IT FURTHER RESOLVED that certified copies of this Concurrent Resolution be transmitted to the Auditor, Director of Commerce and Consumer Affairs, and Insurance Commissioner.
176	176
177	177
178	178
179	179
180	180
181	181
182	182
183	183	OFFERED BY: _____________________________
184	184
185	185
186	186
187	187	OFFERED BY:
188	188
189	189	_____________________________
190	190
191	191
192	192
193	193
194	194
195	195
196	196
197	197	Report Title: Auditor; Social and Financial Impact Assessment Report; Mandatory Health Insurance Coverage; Biomarker Testing
198	198
199	199	Report Title:
200	200
201	201	Auditor; Social and Financial Impact Assessment Report; Mandatory Health Insurance Coverage; Biomarker Testing